Brigida Maiorano
@BrigidaMaiorano
Followers
78
Following
84
Statuses
40
Medical Oncologist, Pianist and Orchestra Conductor
Joined June 2022
RT @montypal: Open up the program book for #GURetreat24 & you will see immediately the uniqueness of @AndreaNecchi’s meeting - no unnecessa…
0
17
0
RT @Anto_cigliola: @_alelarcher kicks of #GURetreat24 with an eccellent overview on #renalcancer 🚀 @AndreaNecchi @CMercinelli @vale_tateo @…
0
3
0
RT @PGrivasMDPhD: @Albert0Briganti superstar! @AndreaNecchi @SanRaffaeleMI @BrigidaMaiorano @CMercinelli @Anto_cigliola @vale_tateo @shilpa…
0
1
0
RT @PGrivasMDPhD: @AndreaNecchi @Albert0Briganti @SanRaffaeleMI amazing GU retreat with stellar speakers, topics, discussions @SpiessPhilip…
0
5
0
RT @Anto_cigliola: San Raffaele Urologic Retreat 3th Edition: let’s start!!#Oncology #SanRaffaele #MedicalResearch #GURetreat24 @AndreaNecc…
0
7
0
#PDL1: a #prognostic but not #predictive role in #urothelialcarcinoma, as stated in our #metanalysis on behalf of the @meeturoIT group! Thanks to all the authors! @MassimoDiMaio75 @g_procopio_ @giandomenicoroviello LindaCerbone EvaristoMaiello
1
2
8
0
1
0
RT @g_procopio_: PD-L1 expression is associated with improved ORR, OS, and PFS for patients with mUC who receive ICIs, but it is unlikely t…
0
4
0
RT @DrChoueiri: ANOTHER PRACTICE-CHANGING TRIAL #ESMO23 Nivo/GC improves survival vs GC! Also rapid, deep and durable responses! Excell…
0
37
0
RT @DrChoueiri: Simply "presidential"! @tompowles1 presents the first combinations thats beats chemotherapy in 1L mUC for survival!! At 17.…
0
69
0
RT @ERPlimackMD: Applause mid-presentation marking the moment the standard of care changed in #bladdercancer The data speaks for itself, b…
0
176
0
RT @tompowles1: Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st lin…
0
500
0
La Camera approva la legge sul diritto all'oblio oncologico
0
0
1
RT @tompowles1: Updated 1st line maintenance avelumab for UC with > 3yrs FU = 24% ⬇️ in death & 46% ⬇️ in PFS. 80% of progressors in the co…
0
45
0
RT @DrRosenbergMSK: Accelerated approval for EV+pembrolizumab- ORR Cohorts A &K of 68%! Potentially transformative for advanced urothelial…
0
29
0
Are all #GI #adverse_effects of #ICI the same? Don't forget infective etiologies! Our letter on @APandT together with my onco-bro @DCiardiello, thanks!
Just out on @APandT 📢 "Be careful of gastrointestinal CMV infection in adverse events from ICIs therapy in solid tumours" It always a pleasure to work my onco-sisters💪 @BrigidaMaiorano Paola Parente
0
0
1
Systematically reviewed #ICIs studies in #Cervicalcancer: more and more #Immunotherapy also in this disease! #mdpicancers via @Cancers_MDPI
Just out on Cancers📢📢📢 Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review. Great work by my Oncology-Sister @BrigidaMaiorano💪 #mdpicancers via @Cancers_MDPI
0
2
4
RT @DCiardiello: Just out on Cancers📢📢📢 Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review. Great work…
0
1
0
Tips about the combination of anti-angiogenics and immunotherapy in #colorectalcancer in our review just published @MDPIOpenAccess! Tnx @DCiardiello for the cooperation!
Just out on Life 📢📢📢 The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer @BrigidaMaiorano
#mdpilife via @Life_MDPI
0
0
1
